In vitro evaluation of alkylcarbonyloxymethyl (ACOM) ethers as novel prodrugs of phenols for topical delivery: ACOM prodrugs of acetaminophen

International Journal of Pharmaceutics

Volumn 346, Issue 1-2, 2008, Pages 80-88

  Thomas, Joshua D ^a   Sloan, Kenneth B ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Diffusion cell experiments; Prodrugs; Roberts Sloan equation; Topical delivery; Transformed Potts Guy equation; Water solubility

Indexed keywords

BUFFER; ETHER DERIVATIVE; MYRISTIC ACID ISOPROPYL ESTER; PARACETAMOL; PHENOL; PRODRUG; SOLVENT;

ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG DELIVERY SYSTEM; DRUG HYDROLYSIS; DRUG SOLUBILITY; FEMALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SKIN PERMEABILITY; SUSPENSION;

ACETAMINOPHEN; ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG DELIVERY SYSTEMS; ETHERS; FEMALE; MICE; MICE, INBRED HRS; MODELS, BIOLOGICAL; PHENOLS; PRODRUGS; SKIN; SOLUBILITY; TRANSITION TEMPERATURE;

EID: 36049052353     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.06.007     Document Type: Article

References (42)

1. Bauguess C.T., Sadik F., Fincher J.H., and Hartman C.W. Hydrolysis of fatty cid esters of acetaminophen in buffered pancreatic lipase systems I. J. Pharm. Sci. 64 (1975) 117-120
2. Beall H.D., and Sloan K.B. Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkylcarbonyl-5-FU prodrugs. Int. J. Pharm. 129 (1996) 203-210
3. Beall H.D., and Sloan K.B. Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyl-5-FU prodrugs. Int. J. Pharm. 217 (2001) 127-137
4. Beall H.D., Getz J.J., and Sloan K.B. The estimation of relative water solubility for prodrugs that are unstable in water. Int. J. Pharm. 93 (1993) 37-47
5. Beall H.D., Prankerd R.J., and Sloan K.B. Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkyloxycarbonyl-5-FU prodrugs: physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm. 111 (1994) 223-233
6. Beaumont K., Webster R., Gardner I., and Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the drug discovery scientist. Curr. Drug Metab. 4 (2003) 461-485
7. Bundgaard H. The double prodrug concept and its applications. Adv. Drug Deliv. Rev. 3 (1989) 39-65
8. Bundgaard H., Klixbull U., and Falch E. Prodrugs as drug delivery systems. 44: O-acyloxymethyl, O-acyl, and N-acyl salicylamide derivatives as possible prodrugs for salicylamide. Int. J. Pharm. 30 (1986) 111-121
9. Drustrup J., Fullerton A., Christrup L., and Bundgaard H. Utilization of prodrugs to enhance the transdermal absorption of morphine. Int. J. Pharm. 71 (1991) 105-116
10. Fedors R.F. A method for estimating both the solubility parameters and molar volumes of liquids. Polym. Eng. Sci. 14 (1974) 147-154
11. Hadgraft J., and Guy R. Feasibility assesment in topical and transdermal delivery: mathematical models and in vitro studies. In: Hadgraft J., and Guy R. (Eds). Transdermal Drug Delivery (2003), Marcel Dekker, New York 1-23
12. Hansen L.B., Fullerton A., Christrup L., and Bundgaard H. Enhanced transdermal delivery of ketobemidone with prodrugs. Int. J. Pharm. 84 (1992) 253-260
13. Hou S.Y.E., Mitra A., White S., Menon G.K., Ghadially R., and Elias P.M. Membrane structures in normal and essential fatty acid-deficient stratum corneum: characterization by ruthenium tetroxide staining and X-ray diffraction. J. Invest. Dermatol. 96 (1991) 215-223
14. Jencks W., and Regenstein J. In: Fasman G. (Ed). Handbook of Biochemistry and Molecular Biology: Physical and Chemical Data (1976), CRC Press, Cleveland 305-351
15. Kerr D., Roberts W., Tebbett I., and Sloan K.B. 7-Alkylcarbonyloxymethyl prodrugs of theophylline: topical delivery of theophylline. Int. J. Pharm. 167 (1998) 37-48
16. Madison K.C., Swartzendruber D.C., Wertz P.W., and Downing D.T. Presence of intact intercellular lipid lamellae in the upper layers of the stratum corneum. J. Invest. Dermatol. 88 (1987) 714-718
17. Martin A., Wu P.L., and Velasquez T. Extended hildebrand solubility approach: sulfonamides in binary and ternary solvents. J. Pharm. Sci. 74 (1985) 277-282
18. McClelland R., Kanagasabapathy V.M., and Mathivanan N. Kinetics of breakdown of arylhemiacetals of alpha-bromoacetophenone: effect of phenol leaving groups on the lifetime of tetrahedral intermediates. Can. J. Chem. 69 (1991) 2084-2093
19. Pillai O., Hamad M., Crooks P., and Stinchcomb A.L. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharm. Res. 21 (2004) 1146-1152
20. Potts R., and Guy R. Predicting skin permeability. Pharm. Res. 9 (1992) 663-669
21. Roberts W., and Sloan K.B. Correlation of aqueous and lipid solubilities with flux for prodrugs of 5-fluorouracil, theophylline and 6-mercaptopurine: a Potts-Guy approach. J. Pharm. Sci. 88 (1999) 515-532
22. Roberts W., and Sloan K.B. Prediction of transdermal flux of prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine with a series/parallel model. J. Pharm. Sci. 89 (2000) 1415-1431
23. Roberts W., and Sloan K.B. Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs. J. Pharm. Sci. 92 (2003) 1028-1036
24. Sloan K.B. Functional group considerations in the development of prodrug approaches to solving topical delivery problems. In: Sloan K.B. (Ed). Prodrugs: Topical and Ocular Drug Delivery (1992), Marcel Dekker, New York 17-116
25. Sloan K.B., and Wasdo S. Designing for topical delivery: prodrugs can make the difference. Med. Res. Rev. 23 (2003) 763-793
26. Sloan K.B., and Wasdo S. The role of prodrugs in penetration enhancement. In: Smith E., and Maibach H. (Eds). Percutaneous Penetration Enhancers (2006), Taylor and Francis, Boca Raton 51-64
27. Sloan K.B., Koch S., Siver K., and Flowers F. The use of solubility parameters of drug and vehicle to predict flux. J. Invest. Dermatol. 87 (1986) 244-252
28. Sloan K.B., Beall H.D., Weimar W.R., and Villaneuva R. The effect of receptor phase composition on the permeability of hairless mouse skin in diffusion cell experiments. Int. J. Pharm. 73 (1991) 97-104
29. Sloan K.B., Getz J.J., Beall H.D., and Prankerd R.J. Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkylaminocarbonyl-5-FU prodrugs: physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm. 93 (1993) 27-36
30. Sloan K.B., Wasdo S., Ezike-Mkparu U., Murray T., Nickels D., Singh S., Shanks T., Tovar J., Ulmer K., and Waranis R.P. Topical delivery of 5-fluorouracil and 6-mercaptopurine by their alkylcarbonyloxymethyl prodrugs from water: vehicle effects on design of prodrugs. Pharm. Res. 20 (2003) 639-645
31. Sloan K.B., Wasdo S.C., and Rautio J. Design for optimized topical delivery: prodrugs and a paradigm change. Pharm. Res. 23 (2006) 2729-2747
32. Stinchcomb A.L., Paliwal A., Dua R., Imoto H., Woodard R.W., and Flynn G.L. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharm. Res. 13 (1996) 1519-1523
33. Stinchcomb A.L., Swaan P., Ekabo O., Harris K., Browe J., Hammell D., Cooperman T., and Pearsall M. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin. J. Pharm. Sci. 91 (2002) 2571-2578
34. Sung K.C., Fang J., and Hu O.Y. Delivery of nalbuphine and its prodrugs across skin by passive diffusion and iontophoresis. J. Control. Rel. 67 (2000) 1-8
35. Taylor H.E., and Sloan K.B. 1-Alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-FU): synthesis, physicochemical properties, and topical delivery. J. Pharm. Sci. 87 (1998) 15-20
36. Thomas, J.D. 2006. Improving the topical delivery of phenol-containing drugs: an alkylcarbonyloxymethyl and alkyloxycarbonyloxymethyl prodrug approach. Ph.D. Dissertation, University of Florida, Gainesville.
37. Valiveti S., Paudel K., Hammell D., Hamad M., Chen J., Crooks P., and Stinchcomb A. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. Pharm. Res. 22 (2005) 981-989
38. Waranis R.P., and Sloan K.B. Effects of vehicles and prodrug properties on the delivery of 6-mercaptopurine through skin: bisacyloxymethyl-6-mercaptopurine prodrugs. J. Pharm. Sci. 76 (1987) 587-595
39. 6-acyloxymethyl-6-mercaptopurine prodrugs. J. Pharm. Sci. 77 (1988) 210-215
40. Wasdo, S.C. 2005. Topical delivery of a model phenolic compound: alkyloxycarbonyl prodrugs of acetaminophen. Ph.D. Dissertation, University of Florida, Gainesville.
41. Wasdo S.C., and Sloan K.B. Topical delivery of a model phenolic drug: alkyloxycarbonyl prodrugs of acetaminophen. Pharm. Res. 21 (2004) 940-946
42. Williams A. Transdermal and Topical Drug Delivery (2003), Pharmaceutical Press, London